TDM-based imipramine treatment in neuropathic pain

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 352-360

  Rasmussen, Peter Vestergaard ^a   Jensen, Troels S ^a   Sindrup, Søren H ^b   Bach, Flemming W ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Allodynia; Imipramine; Neuropathic pain; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; IMIPRAMINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; AGNOSIA; ALLODYNIA; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HYPERALGESIA; INCISION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION INVENTORY; MALE; MASTECTOMY; MCGILL PAIN QUESTIONNAIRE; NERVE COMPRESSION; NERVE PLEXUS; NERVE ROOT INJURY; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NERVE INJURY; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; SCAR; SIDE EFFECT; TREATMENT FAILURE;

ADULT; AGED; ANALGESICS, NON-NARCOTIC; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 3342922282     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00003     Document Type: Article

References (31)

1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
2. Sindrup SH, Jensen TS. Antidepressants in the treatment of neuropathic pain. In: Hansson P, Field HL, Hill RG, et al, eds. Neuropathic Pain: Pathophysiology and Treatment. Seattle: IASP Press; 2001:169-183.
3. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA. 1980;243:1147-1150.
4. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589-596.
5. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45: 3-9.
6. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326: 1250-1256.
7. Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol. 1989;37: 151-153.
8. Sindrup SH, Gram LF, Skjold T, et al. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther. 1990;47:509-515.
9. Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA. 1984;251:1727-1730.
10. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988;38:1427-1432.
11. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpctic neuralgia. Clin Pharmacol Ther. 1990;47:305-312.
12. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996;64:293-302.
13. Leijon G, Boivie J. Central post-stroke pain-a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27-36.
14. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J. 1995;310:452-454.
15. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
16. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39:533-537.
17. Bergmann TK, Bathum L, Brosen K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur J Clin Pharmacol. 2001;57:123-127.
18. Bathum L, Johansson I, Ingelman-Sundberg M, et al. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics. 1998;8: 119-123.
19. Reisby N, Gram LF, Bech P, et al. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology (Berl). 1977;54:263-272.
20. Pedersen OL, Gram LF, Kristensen CB, et al. Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol. 1982; 23:513-521.
21. Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain? Pain. 1998;77:227-229.
22. Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain. 2001;94:131-132.
23. Farrar JT, Young JPJ, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
24. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30: 191-197.
25. Drewes AM, Helweg-Larsen S, Petersen P, et al. McGill Pain Questionnaire translated into Danish: experimental and clinical findings. Clin J Pain. 1993;9:80-87.
26. Bech P, Rasmussen N, Olsen LR, et al. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Effect Disord. 2001;66:159-164.
27. Gottrup H, Nielsen J, Arendt-Nielsen L, et al. The relationship between sensory thresholds and mechanical hyperalgesia in nerve injury. Pain. 1998;75:321-329.
28. Olesen OV, Plougmann P, Linnet K. Determination of nortriptyline in human serum by fully automated solid-phase extraction and on-line high-performance liquid chromatography in the presence of anti psychotic drugs. J Chromatogr B. 2000;746:233-239.
29. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42:135-144.
30. McLeod DR, Hoehn-Saric R, Porges SW, et al. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000;20: 615-621.
31. Sindrup SH, Brosen K, Gram LF. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monit. 1990;12:445-449.